Cytodel
Preclinical biopharmaceutical company developing recombinant botulinum toxin (rBoT) derivatives and antibody fusion proteins to deliver therapeutic payloads to the neuronal cytoplasm. Platform is intended to enable intraneuronal delivery of antibodies and design of "biobetter" rBoT therapeutics for biodefense and neurologic indications, with demonstrated preclinical activity in multiple animal species and an associated patent portfolio.
Industries
Nr. of Employees
small (1-50)
Products
Cyto-111 (intraneuronal antibody fusion therapeutic)
A post-symptomatic intraneuronal antibody fusion protein designed to deliver an antibody payload to the neuronal cytoplasm as an antidote to internalized neurotoxin; demonstrated safety and activity in multiple species.
Cyto-014 (engineered biobetter recombinant neurotoxin)
A de-novo designed recombinant neurotoxin molecule engineered to reduce systemic toxicity and increase maximum tolerated dose in animal models to improve safety and effectiveness for large muscle group treatments.
Discovery Programs (modular intraneuronal antibody discovery)
Research programs applying the modular intraneuronal delivery platform to identify and develop antibody-based therapeutics targeting previously inaccessible intraneuronal proteins.
Cyto-111 (intraneuronal antibody fusion therapeutic)
A post-symptomatic intraneuronal antibody fusion protein designed to deliver an antibody payload to the neuronal cytoplasm as an antidote to internalized neurotoxin; demonstrated safety and activity in multiple species.
Cyto-014 (engineered biobetter recombinant neurotoxin)
A de-novo designed recombinant neurotoxin molecule engineered to reduce systemic toxicity and increase maximum tolerated dose in animal models to improve safety and effectiveness for large muscle group treatments.
Discovery Programs (modular intraneuronal antibody discovery)
Research programs applying the modular intraneuronal delivery platform to identify and develop antibody-based therapeutics targeting previously inaccessible intraneuronal proteins.
Expertise Areas
- Intraneuronal drug delivery
- Recombinant protein engineering
- Antibody fusion therapeutics
- Preclinical development and animal efficacy studies
Key Technologies
- Antibody fusion proteins (AFPs)
- Recombinant neurotoxin-derived delivery vehicles
- Intraneuronal cytoplasmic delivery
- Recombinant protein expression systems
News & Updates
Press release describing preclinical data on an intraneuronal antibody fusion protein antidote to botulinum neurotoxin published in Science Translational Medicine.
Peer-reviewed publication reporting therapeutic effects from intraneuronal delivery of antibodies in animal models of botulism (Jan 2021).
Publication describing engineering of neurotoxin C1 derivatives as a molecular vehicle for intraneuronal delivery (Feb 2017).
Preclinical study documenting a recombinant neurotoxin derivative engineered for improved safety (Aug 2016).
Press release describing preclinical data on an intraneuronal antibody fusion protein antidote to botulinum neurotoxin published in Science Translational Medicine.
Peer-reviewed publication reporting therapeutic effects from intraneuronal delivery of antibodies in animal models of botulism (Jan 2021).
Publication describing engineering of neurotoxin C1 derivatives as a molecular vehicle for intraneuronal delivery (Feb 2017).
Preclinical study documenting a recombinant neurotoxin derivative engineered for improved safety (Aug 2016).